Microbial Population Changes and Their Relationship with Human Health and Disease by Álvarez Mercado, Ana Isabel et al.
microorganisms
Review
Microbial Population Changes and Their
Relationship with Human Health and Disease
Ana Isabel Álvarez-Mercado 1,2,* , Miguel Navarro-Oliveros 2, Cándido Robles-Sánchez 1,2,
Julio Plaza-Díaz 1,2,3,* , María José Sáez-Lara 4 , Sergio Muñoz-Quezada 5,6,
Luis Fontana 1,2,3,† and Francisco Abadía-Molina 2,7,*,†
1 Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada,
18071 Granada, Spain; croblesan@hotmail.com (C.R.-S.); fontana@ugr.es (L.F.)
2 Institute of Nutrition and Food Technology “José Mataix,” Center of Biomedical Research,
University of Granada, Avda. del Conocimiento s/n. 18016 Armilla, Granada, Spain; miguelno@ugr.es
3 Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada,
18014 Granada, Spain
4 Department of Biochemistry and Molecular Biology I, School of Sciences, University of Granada,
18071 Granada, Spain; mjsaez@ugr.es
5 Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile,
Santiago 6094411, Chile; chechomu@hotmail.com
6 National Agency for Medicines (ANAMED), Public Health Institute, Santiago 7780050, Chile
7 Department of Cell Biology, School of Sciences, University of Granada, 18071 Granada, Spain
* Correspondence: analvarezmercado@gmail.com (A.I.A.-M.); jrplaza@ugr.es (J.P.-D.);
fmolina@ugr.es (F.A.-M.); Tel.: +34-9-5824-1000 (ext. 41599) (J.P.-D.)
† These authors contributed equally to this work.
Received: 30 January 2019; Accepted: 27 February 2019; Published: 3 March 2019


Abstract: Specific microbial profiles and changes in intestinal microbiota have been widely
demonstrated to be associated with the pathogenesis of a number of extra-intestinal (obesity and
metabolic syndrome) and intestinal (inflammatory bowel disease) diseases as well as other metabolic
disorders, such as non-alcoholic fatty liver disease and type 2 diabetes. Thus, maintaining a healthy
gut ecosystem could aid in avoiding the early onset and development of these diseases. Furthermore,
it is mandatory to evaluate the alterations in the microbiota associated with pathophysiological
conditions and how to counteract them to restore intestinal homeostasis. This review highlights
and critically discusses recent literature focused on identifying changes in and developing gut
microbiota-targeted interventions (probiotics, prebiotics, diet, and fecal microbiota transplantation,
among others) for the above-mentioned pathologies. We also discuss future directions and promising
approaches to counteract unhealthy alterations in the gut microbiota. Altogether, we conclude that
research in this field is currently in its infancy, which may be due to the large number of factors that
can elicit such alterations, the variety of related pathologies, and the heterogeneity of the population
involved. Further research on the effects of probiotics, prebiotics, or fecal transplantations on the
composition of the human gut microbiome is necessary.
Keywords: gut microbiota; microbial population changes; randomized clinical trial; health status;
obesity; non-communicable diseases; non-alcoholic fatty liver disease; inflammatory bowel disease
1. Introduction
Health is defined as “the state of the organism when it functions optimally without evidence of
disease,” and the words “microbes” or “microorganism” are surprisingly missing in this definition.
Currently, sequencing technologies (e.g., next-generation sequencing technologies) have stimulated
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new research that relates the microbial communities that reside in our gut with a number of
physiological conditions. In 2014, the term microbiota was defined as the “full collection of microbes
(bacteria, fungi, and viruses, among others) that naturally exist within a particular biological niche,”
an estimated 500–1000 species [1–3] that may have a tremendous impact on human health.
The gut microbiota is regulated by an enormous number of factors, such as microbiological factors,
host characteristics, diet patterns, and environmental variables [4]. Some protective, structural, and
metabolic functions have been reported for gut microbiota [5], and these functions are associated
with the regulation of homeostasis and host health. Host defenses against pathogens are in part
mediated through the activity of the gut microbiota, requiring an intimate interpretation of the current
microenvironment to discriminate between commensal and transient bacteria [6,7].
The intestinal epithelium is constantly exposed to high levels of food and bacterial antigens.
Under normal physiological conditions, the intestinal epithelial monolayer facilitates a controlled and
selective flux of components between the lumen and the underlying mucosa [8]. The intestine and the
gut-associated lymphoid tissue are essential components of the immune defense system, protecting the
host from foreign antigens and pathogens while tolerating commensal bacteria and dietary antigens.
Antigen-presenting cell populations in the gut dictate in part the homeostasis between tolerance and
immunity in the intestine, and the dysregulation of this balance can contribute to the pathogenesis
of numerous inflammatory conditions [9]. All of the aforementioned cells are involved in the host
response, and their function principally involves the maintenance of homeostasis.
Endogenous and exogenous factors influence the gut microbiota [10,11] including the mode of
delivery of a neonate [12], host genetic features [13], host immune response [14], diet [15] (including
dietary supplements, breast-feeding, and formula-feeding), xenobiotics (including antibiotics) and
other drugs [16,17], infections [18], diurnal rhythm [19], and environmental microbial exposures [20,21].
Despite evidence linking dysbiosis of the gut microbiota with disease manifestations at sites distant
from the gut, most studies have not explored mechanisms outside the affected site, nor have they
considered the effect of the microbiota and its varied products on the multitude of molecular
pathways potentially involved [21]. Overall, our current understanding of the precise relationships
between the human gut microbiome and disease remains limited. Case–control studies often
report disease-associated microbial dysbiosis, defined as the alteration in terms of the diversity,
quantity, and stability of resident commensal communities relative to the community found in healthy
individuals [3,22].
Probiotics are defined as “live microorganisms that confer a health benefit to the host when
administered in adequate amounts, although dead bacteria and bacterial molecular components may
also exhibit probiotic properties” [23], whereas a prebiotic is a non-viable food component that confers
a health benefit to the host and is associated with the modulation of the intestinal microbiota [3]. The
combination of prebiotics and probiotics is referred to as synbiotics [3,24,25].
A healthy host–microorganism balance contributes to optimally perform metabolic and immune
functions as well as prevent disease development. Indeed, alterations in the delicate host–microbe
relationship is nowadays recognized as associated with a wide variety of diseases such as cancer,
neurological, ophthalmological, premature newborn, extra-intestinal and intestinal diseases, and
metabolic disorders, such as non-alcoholic fatty liver disease and type 2 diabetes (T2D) [26].
However, the specific changes in the intestinal microbiome that are associated with these pathologies
remain unelucidated.
To shed some light on this matter, a comprehensive search of the relevant literature reported
during the last five years was performed in multiple electronic databases, including MEDLINE
(PubMed), EMBASE, and the Cochrane Library. MEDLINE was searched through PubMed for
scientific articles in English using the terms “microbiota” combined with “obesity,” “inflammatory
bowel disease,” “non-alcoholic fatty liver disease,” “insulin resistance syndrome,” and “diabetes
mellitus type 2”. The gut microbiota changes associated with the following conditions are reviewed:
(1) obesity—antibiotics and obesity, gut microbiota and children’s obesity, bariatric surgery and the
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gut microbiota, potential gut microbiota biomarkers in obesity, and clinical trials; (2) inflammatory
bowel disease—ulcerative colitis, and Crohn’s disease; (3) non-alcoholic fatty liver disease; (4) insulin
resistance syndrome; and (5) diabetes mellitus type 2.
2. Gut Microbiota Changes in Particular Pathologies
2.1. Obesity
The prevalence of obesity is increasing worldwide [27,28] and currently represents a major health
problem in both adults and children. The etiology of obesity has been associated with diverse factors,
such as dietary, environmental, educational, and genetic factors. However, these factors do not fully
explain the global incremental rise in obesity, and microbiota traits have recently been shown to play a
causative role in obesity [29,30], demonstrating the potential of the microbiota as a therapeutic target
in obesity. Here we present evidence-based studies linking host gut bacteria to obesity.
2.1.1. Antibiotics and Obesity
Antibiotic exposure has an overwhelming impact on the gut microbiota [31]. Epidemiological
studies have shown that the administration of antibiotics during childhood is associated with a major
risk of obesity [32,33]. Well-known studies have demonstrated the correlation between obesity and the
intestinal microbiota balance [34,35]. These investigations showed an obesity-associated decrease in
the phylum Bacteroidetes and an increase in the phylum Firmicutes, alterations in the gut microbiota
that have been confirmed in animal models that exhibit fat accumulation due to an alteration of host
metabolism [36,37]. Early life exposure to antibiotics has also been suggested to lead to obesity [38].
Interestingly, a decrease in the number of antiobesogenic bacteria (bifidobacteria and Bacteroides)
after repeated exposure to antibiotics in neonates has been described [39]. Moreover, several studies
have reported a correlation between childhood body mass index (BMI) and the risk of developing
obesity later in life with antibiotics consumption [32,33,40–43]. Clearly, as revealed from extensive
cohort, multicenter studies, gut microbiome alterations induced by antibiotics may promote obesity
in adulthood, emphasizing the need for additional research on the relationships among antibiotic
exposure, the intestinal microbiota balance, and the susceptibility to develop obesity.
2.1.2. Gut Microbiota and Childhood Obesity
The aforementioned alterations in gut bacteria have been very recently confirmed in children.
An elevated abundance of Firmicutes and a decreased abundance of Bacteroidetes have been shown
to correlate with overweight and obesity [44]. Interestingly, Bacteroidetes have been shown to be
a better predictor of BMI than Firmicutes, possibly due to a higher variability of Firmicutes. This
phenomenon may explain the results of a microbiome profiling study of eight obese children in whom
the phylum Bacteroidetes exhibited the aforementioned tendency while Firmicutes showed little
variation compared to the controls [45]. The levels of short chain fatty acids (SCFAs), the end products
of fermentation of dietary fibers by the anaerobic intestinal microbiota, have been shown to be higher
in obese children [44,46,47], suggesting that gut dysbiosis and augmented intestinal fermentation must
be considered to be among the factors involved in the etiology of infant obesity. Interestingly, the use
of prebiotics has been shown in a recent study to alter the intestinal microbiota and reduce body fat
in obese or overweight children [48]. Personalized nutrition [49,50], the use of prebiotics, probiotics,
postbiotics, and synbiotics [51], fecal microbiota transplantation (FMT) [52,53], dietary education [54],
and physical activity [55] constitute the primary approaches aimed at using the gut microbiota as a
therapeutic target for obesity in children. In a prospective study of 70 children within a four-year
window, pre-obese dysbiotic gut and dietary habits were correlated with excessive weight gaining [56].
Microorganisms 2019, 7, 68 4 of 27
2.1.3. Bariatric Surgery and the Gut Microbiota
The gut microbiota has been shown to mediate the metabolic benefits and weight loss observed
after bariatric surgery. Bariatric surgery alters the expression of several genes involved in metabolic
pathways, which induces changes in the gut microbiota composition [57–60]. Given the relationship
between the gut microbiota and the metabolic health of an individual, there is a growing interest in
understanding the modifications that occur in intestinal microbiota after bariatric surgery and how
these changes lead to weight loss and a better metabolic profile. Microbiome analyses following
Roux-en-Y gastric bypass (RYGB) or vertical banded gastroplasty have shown similar long-term effects
on gut microbiota and fat loss [61]. In mice, RYGB has been shown to induce a rapid and maintained
increase in the presence of Gammaproteobacteria (Escherichia) and Verrucomicrobia (Akkermansia) [62]. A
study of microbiome modifications in 13 obese patients after bariatric surgery reported an increase
in gut microbial diversity and identified alterations in the relative abundances of 31 species [63].
These changes in microbiota occurred in parallel with weight loss and functional and metabolic
improvements: (i) an increased potential to assimilate multiple energy sources using transporters and
phosphotransferase system, (ii) a better use of aerobic respiration, and (iii) the use of amino acids and
fatty acids as energy sources.
Very recently, an investigation of a cohort of lean and obese individuals identified a distinct
causal role of the gut microbiota in the development of obesity [64]. Liu et al. associated changes
in microbiota composition of some obesity-related microbial species with circulating metabolites. In
particular, the abundance of a glutamate-fermenting commensal species, Bacteroides thetaiotaomicron,
was notably decreased in obese individuals and was inversely correlated with serum glutamate
concentration. Furthermore, these authors reported that, after bariatric surgery, several microbial
enzymatic functions become more similar to those of lean controls, including pathways involved in
carbohydrate fermentation, citrate cycle, glycosaminoglycan degradation, and lipopolysaccharide
(LPS) synthesis, as well as the production of aromatic amino acid and branched chain amino acids
(BCAA), suggesting that weight-loss intervention by bariatric surgery reversed, at least partially,
the reported obesity-associated microbial and metabolic alterations. Very recently, decreased gut
microbial gene richness (MGR) has been associated with severe obesity [22] and, although bariatric
surgery increased MGR one year after surgery, most RYGB patients remained with low MGR one
year post-surgery, which emphasizes the need of additional strategies to improve the dysbiosis
in severe obesity. Table 1 summarizes the changes in gut microbiota associated with obesity and
microbiota-targeted interventions for this disease.
2.1.4. Potential Gut Microbiota Biomarkers of Obesity
The use of metagenomics analyses to link obesity and the gut microbiota allows for the
specific bacterial strains to be identified as potential biomarkers of obesity and of the development
or progression obesity. Dominant bacterial phyla that are consistently identified in the guts of
normal individuals include Firmicutes, Bacteroidetes, and Actinobacteria, with Verrucomicrobia
and Proteobacteria being present at lower abundances [65,66]. It has been recently described that
microbiota markers in adolescent and adult obese patients show different age-dependent traits [67]. In
particular, Faecalibacterium prausnitzii and Actinomyces have been assigned to the microbiota of obese
adolescents, whereas Bacteroides caccae, Barnesiellaceae, Parabacteroides, Rikenellaceae, and Oscillospira
have been assigned to the microbiota of adolescents with normal weights. F. prausnitzii participates in
the fermentation of non-absorbed carbohydrates, and its abundance in the guts of obese adolescents
may contribute to increased energy recovery, leading to a higher dietary energy intake that may in turn
contribute to the lower success of weight loss diets reported for individuals with a higher abundance
of F. prausnitzii [68]. Other reports associate the butyrate production capacity of F. prausnitzii with
a healthy state [69–71], an apparent contradiction that emphasizes the need of future studies using
broader cohorts to identify distinct microbial biomarkers that can unequivocally associate obesity with
a given microbiota profile.
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Table 1. Microbiota changes associated with obesity.
Reference Characteristics Disease Method Primary Results
Turnbaugh et al., 2009
[34]
154 adult female
monozygotic and
dizygotic twin pairs
concordant for leanness
or obesity
Obesity Sequencing(16S rRNA)
Gut microbiomes are shared among
family members, but the gut microbial
community varies in each individual.
Ignacio et al., 2016
[40]
Correlation between
BMI and fecal
microbiota in
84 children
Obesity qRT-PCR
Significant association between the
number of Lactobacillus spp. and B.
fragilis group members and BMI.
Riva et al., 2017 [44]
Characterization of the
gut microbiota in
78 obese and
normal-weight children
aged 6 to 16
Obesity Sequencing(16S rRNA)
Elevated levels of Firmicutes and
depleted levels of Bacteroidetes.
Nicolucci et al., 2017
[48]
42 obese children who
received either
oligofructose-enriched
inulin or placebo
Obesity Sequencing(16S rRNA)
Significant increases in species of the
genus Bifidobacterium and decreases in
B. vulgatus within the group that
consumed oligofructose-enriched inulin.
Zhang et al., 2015 [54]
Intervention trial in
38 Prader-Willi
syndrome and simple
obesity children.
Prader-Willi
syndrome and
obesity
Analysis of
prevalent bacterial
draft genomes
assembled directly
from metagenomic
datasets
Non-digestible carbohydrates induced
significant weight loss and concomitant
structural changes in the gut microbiota.
Bai et al., 2018 [55]
267 children (7–18 years
old) analyzed according
to their lifestyles
Obesity Sequencing(16S rRNA)
Lower BMI and exercise frequency were
associated with depleted Actinobacteria;
Proteobacteria was significantly enriched
in individuals with higher BMI levels;
and Firmicutes was significantly
enriched in individuals participating in
frequent exercise.
Rampelli et al., 2018
[56]
70 children analyzed in
a two-time point 4-year
prospective study
Pre-obese Sequencing(16S rRNA)
Pre-obese dysbiosis and unhealthy diets
were correlated and suggested to be
predictors of obesity.
Tremaroli et al., 2015
[61]
Gut microbiome
analysis of 14 women
9.4 years after bariatric
surgery was performed
Obesity
High-quality
Illumina reads
alignment analysis
Bariatric surgery induces long-term
alterations in the human gut microbiome.
Surgically altered microbiomes
contribute to fat mass regulation.
Palleja et al., 2016 [63]
Gut microbiome
analysis 1 and 3 months
after bariatric surgery in
13 patients
Obesity
Shotgun
metagenomic
sequencing
31 microbial species showed altered
relative abundances within the first
3 months, 16 of which maintained their
altered relative abundances 1 year after
surgery. F. prausnitzii was the only
species that decreased in
relative abundance.
Liu et al., 2017 [64]
Gut microbiome
analysis of obese and
post-bariatric
intervention individuals
in a cohort of 257 lean
and obese young
individuals
Obesity Metagenome-wideassociation
Abundance of B. thetaiotaomicron was
markedly decreased in obese individuals.
Bariatric surgery intervention reversed
obesity associated microbial alterations,
including the decreased abundance of
B. thetaiotaomicron.
Aron-Wisnewsky et al.
[22]
61 severely obese
subjects of whom 24
were followed 1, 3, and
12 months post-bariatric
surgery
Obesity Shotgunmetagenomics
Although bariatric surgery increased
MGR one year after surgery, most RYGB
patients remained with low MGR one
year postsurgery.
Del Chierico et al.,
2018 [67]
Gut microbiome
analysis of 69 adolescent
and adult patients
Obesity Sequencing(16S rRNA)
Microbial markers, F. prausnitzii and
Actinomyces assigned to the microbiota of
obese adolescents. Parabacteroides,
Rikenellaceae, Bacteroides caccae,
Barnesiellaceae and Oscillospira were
assigned to the microbiota of normal
weight adolescents.
Le Chatelier et al.,
2013 [68]
Gut microbiome
analysis of 292
adult patients
Obesity Sequencing(16S rRNA)
Individuals with low bacterial richness
are characterized by increased overall
adiposity compared to high bacterial
richness individuals.
Abbreviations: BMI: body mass-index; MGR: microbial gene richness; qRT-PCR: quantitative polymerase chain
reaction; rRNA: ribosomal ribonucleic acid; RYGB: Roux-en-Y gastric bypass.
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2.1.5. Clinical Trials
Of the 123 active clinical trials annotated to date in ClinicalTrials.gov (not finished or completed)
that consider the gut microbiota as a therapeutic target in obesity, 55 (44.7%) employ dietary
supplements or modifications in the diets of individuals in their interventions, 21 (17.07%) propose the
use of probiotics, prebiotics, or synbiotics, 15 (12.2%) analyze the microbiota after bariatric surgery,
9 (7.3%) perform fecal transplantation interventions, 12 (9.7%) institute changes in patient lifestyle
(ranging from exercise to mindfulness), 4 (3.2%) use approved drugs to adjust the gut microbiota, and
7 (5.7%) are strictly observational analyses. The important role of the gut microbiota in the alteration
of the physiological systems involved in obesity is reflected by the wide variety of therapies based on
counteracting their pathological modifications.
2.2. Inflammatory Bowel Disease
Crohn’s disease (CD) and ulcerative colitis (UC) are the primary pathological conditions associated
with IBD and are described as a chronic and non-specific inflammation of the gastrointestinal tract [72].
There is some information regarding the correlation between changes in the gut microbiota and
the development of IBD [73,74]. Regarding microbiota profiles, some studies have reported lower
relative abundances of Alistipes finegoldi and Alistipes putredinis, as well as Firmicutes, Tenericutes, and
Bacteroidetes in patients with IBD [75].
2.2.1. Ulcerative Colitis
The gut microbiota associated UC is characterized by a high ratio of B. fragilis/F. prausnitzii and a
low abundance of butyrate-producing bacteria (BPB) [76]. Some studies have described a decrease in
bifidobacteria [73], Akkermansia municiphila [77], and Clostridium clusters IV, XIVa, and XVIII [78] in
patients with UC compared with the control groups. Two recent studies have reported an increased
diversity in Clostridium cluster XIVa in UC patients [77] as well as increases in the abundances of
Bacteroidetes, Bacilli, Proteobacteria, and Clostridium clusters IX and XI [78]. Recently, Bacteroidetes
has been reported to be absent in patients with active UC [79]. These conflicting results regarding the
Bacteroidetes phylum might be explained by the different status of the UC disease.
FMT is currently being considered as a potential future therapeutic approach to restore normal
intestinal microbiota. FMT-treated patients exhibit different outcomes with respect to their gut
microbiota composition depending on whether they respond to the transplant. Thus, non-responders
show significantly higher levels of Bacteroidetes versus responders [80,81]. In addition, patients in
remission have augmented levels of Barnesiella spp., Parabacteroides spp., Clostridium cluster IV, and
Ruminococcus species [82,83].
Interesting changes in intestinal microbiota have been described after pharmacological treatments.
Patients treated with mesalazine exhibited decreases in the abundances in Bifidobacterium and
Lactobacillus and increases in the abundances of Klebsiella, Proteus, Citrobacter, and hemolytic
Escherichia coli [84]. After treatment with andecaliximab, the presence of Clostridia and Akkermansia
was observed in patients with active UC [85]. Patients treated with vedolizumab and those with
non-remission showed increased levels of Streptococcus salivarius [86], and corticosteroid treatment
was observed to be related to an increase in the abundances of bifidobacteria and Clostridium and a
decrease in that of Faecalibacterium [87].
Regarding the use of probiotics, Matsuoka et al. have described that the administration of
Bifidobacterium breve Yakult to UC patients barely had an effect, with the only change being in the relative
abundance of Clostridium leptum, which significantly increased [88]. However, Ananthakrishnan et al.
have suggested that early clinical remission of UC patients could be predicted by microbial composition
only at baseline with a weaker influence at the level of the species or genus [87].
As for the impact of diet on the gut microbiota of UC patients, a low fat diet has been reported to
increase the presence of Bacteroidetes after four weeks of intervention [89].
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2.2.2. Crohn’s Disease
Recent investigations have described lower levels of Clostridium coccoides, Clostridium leptum and
Faecalibacterium prausnitzii and a higher abundance of Escherichia coli in patients with CD [90].
A significant increase in Escherichia coli was reported in patients with CD subjected to FMT [91].
Another study investigating FMT in CD patients described decreases in the abundances of Bacteroides,
Roseburia, Phascolarctobacterium, and Eubacterium along with increases in those of Bilophila, Streptococcus,
Clostridium, and Paraprevotella [92].
Infliximab treatment has been reported to increase the abundance of Clostridiales in responders
versus relapsing patients [93]. Similarly, ustekinumab has been shown to increase Faecalibacterium in
responders compared with relapsing patients [94].
Diet is an important variable in the treatment of patients with CD. The administration
of fermentable oligosaccharides, disaccharides, monosaccharides and polyols was observed to
increase the levels of Clostridium cluster XIVa and Akkermansia municiphila, whereas that of
Faecalibacterium prausnitzii was unaffected [95]. With the objective of evaluating differences in the
microbial profiles associated with exclusive enteral nutrition and corticosteroid administration, the
authors of one study observed a decrease in Prevotella, bifidobacteria, and Enterobacteriaceae in both
assayed treatments [87]. Table 2 summarizes changes in gut microbiota associated with intestinal
diseases and microbiota-targeted interventions for these diseases.
Table 2. Microbiota changes associated with inflammatory bowel disease.
Reference Disease Intervention Primary Results Method
Sitkin et al., 2018 [76] 40 UC patients - High B. fragilis/F. prausnitzii,depleted BPB, low Bifidobacterium. qRT-PCR
Ishikawa et al., 2018 [81] 36 UC mild–severepatients FMT+AFM pretreatment Bacteroidetes were recovered.
Sequencing
(16S rRNA)
Matsuoka et al., 2018
[88]
43 UC remission
patients, 20–70 y/o
Bifidobacterium breve
Yakult Increase in C. leptum. qRT-PCR
Phillips et al., 2018 [89] UC quiescent Low fat diet High Bacteroidetes. -
Ananthakrishnan et al.,
2017 [86] 43 UC patients Vedolizumab
In non-remission, high S.
salivarius.
Sequencing
(V4 16S rRNA)
Lamere et al. 2017 [85] 59 UC patients Andecaliximab High Clostridia and Akkermansia. Sequencing
Fuentes et al., 2017 [80] 33 UC mild–moderatepatients FMT
Low Clostridium cluster XIVa,
non-responders had high
Bacteroidetes.
Sequencing
(16S rRNA)
Dobrolyubova et al.,
2017 [84]
162 UC patients,
35–41 y/o 5-ASA
In remission, low Bifidobacilles and
Lactobacillus, high Klebsiella,
Proteus, Citrobacter, and hemolytic
E. coli.
-
Lee et al., 2016 [79]
22 UC active and
remission patients,
>18 y/o
- Bacteroidetes absent in patientswith active UC.
Sequencing
(16S rRNA)
De Caro et al., 2016 [73]
14 UC active and
remission patients,
mean 39 y/o
Infliximab, adalimumab,
azathioprine or 5-ASA Low bifidobacteria. Metagenomic
Paramsothy et al., 2016
[82] 81 UC patients FMT
Barnesiella was associated with
remission; Fusobacterium and
Sutterella were associated with a
lack of remission.
Sequencing
(16S rRNA)
Hart et al., 2016 [87] 7 UC patients, 5–18 y/o CS
High bifidobacteria and
Clostridium and low
Faecalibacterium.
Sequencing
(16S rRNA)
Rossen et al., 2015 [78] 58 mild–moderate UCpatients -
Low Clostridium clusters IV, XIVa
and XVIII and high in
Bacteroidetes, Bacilli,
Proteobacteria and Clostridium
cluster IX and XI.
qRT-PCR
James et al., 2014 [77] 37 UC patients, >18 y/o -
UC patients have more
Clostridium cluster XIVa. Lower
A. muciniphila.
qRT-PCR
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Table 2. Cont.
Reference Disease Intervention Primary Results Method
Doherty et al., 2017 [94] 350 moderate–severeCD patients, 18–76 y/o Ustekinumab
High Faecalibacterium in
responders and
remission patients.
Sequencing
(V4 16S rRNA)
Zhou et al., 2017 [93] 16 CD patients Infliximab Incremental change inClostridiales.
Sequencing
(V4 16S rRNA)
Yang et al., 2017 [92] 31 active CD patients FMT
Low Bacteroides, Roseburia, and
Phascolarctobacterium, Eubacterium;
high Bilophila, Streptococcus,
Clostridium and Paraprevotella.
Sequencing
(V4 16S rRNA)
Hart et al., 2016 [87] 22 CD patients, 5–18 y/o EEN or CS
Decreased in Prevotella,
Bifidobacteria and
Enterobacteriaceae.
Sequencing
(16S rRNA)
Halmos et al., 2015 [95] 8 quiescent CD patients FODMAP diet
Increased Clostridium cluster XIVa
and A. muciniphila. F. prausnitzii
was unaltered.
-
Suskind et al., 2015 [74] 9 mild–moderate CDpatients, 12–19 y/o FMT
High E. coli in response to
inflammation.
Sequencing
(V4 16S rRNA)
Rajca et al., 2015 [90] 19 relapser and 14non-relapser patients -
Low C. coccoides, C. leptum and
F. prausnitzii; high E. coli.
Sequencing
(V4 16S rRNA)
Abbreviations: 5-ASA: mesalazine; AFM: amoxicillin-fosfomycin-metronidazole; BPB: butyrate-producing bacteria;
CD: Crohn’s disease; CS: corticosteroid; EEN: exclusive enteral nutrition; FMT: fecal microbiota transplantation;
FODMAP: fermentable oligo-di-mono-saccharides and polyols; IBD: inflammatory bowel disease; qRT-PCR;
quantitative polymerase chain reaction; rRNA: ribosomal ribonucleic acid; UC: ulcerative colitis; V4: hypervariable
16S region; y/o: years old.
2.3. Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is characterized by an incremental increase in fat
accumulation in the form of micro- and macrovacuoles of lipids in hepatocytes [96]. This disease is
closely related to obesity and metabolic syndrome and exhibits features associated with abdominal
obesity, insulin resistance, glucose intolerance, and T2D [97,98].
In addition to general overnutrition, specific diet factors, such as an elevated intake of sugar
and/or fat, and genetic factors are crucial for its pathogenesis and progression [99]. Thus, an
elevated body weight appears to not be the only risk factor associated with NAFLD [100], although
alterations in gut microbiota have been reported as promoting the development of NAFLD by
mediating inflammation, insulin resistance, bile acids, and choline metabolism [101]. Nevertheless,
neither the pathophysiology of NAFLD nor the gut microbiota alterations in patients suffering for
NAFLD have been completely characterized, and there are currently no effective drug therapies for
NAFLD [102], with weight loss via diet and lifestyle modifications being the most successful care
recommendations [103].
Host responses to changes in microbiota metabolism lead to an overwhelming presence of
gut-derived microbial products and the activation of innate immunity and inflammation, resulting
in the development of NAFLD. The presence of the dysbiotic microbiota and an altered intestinal
barrier, possibly associated with disruption of tight-junctions (“leaky gut”), promotes the translocation
of several bacterial products into the portal circulation. The interaction of bacterial products with
toll-like receptors (TLRs) on the hepatic cell surface promotes the progression from simple steatosis to
inflammation and fibrosis of the liver. For instance, the presence of H. pylori has been shown to induce
gastric atrophy, with consequent acid losses predisposing small intestinal bacterial overgrowth, leaky
gut, and portal endotoxin translocation [104].
Thus, interventions targeting the gut–liver axis through modulation of the gut microbiota by
diet and/or pharmacological strategies appear to be a safe and sustainable tool to manage NAFLD.
Manipulation of the gut microbiota has been primarily achieved through the use of probiotics,
prebiotics, or symbiotic supplementation as well as through dietary intervention. For instance, very
recently, Wang et al. reported that the alterations in the levels of bile acids (BAs) by gut bacteria
through an isocaloric Mediterranean dietary intervention in 48 NAFLD patients did not alter fecal
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BA levels. Fecal BA levels and the microbiome do not appear to be responsible for the improvement
in hepatic steatosis observed during dietary intervention in these patients [105]. In this respect and
contrary to expectations, a study performed with 100 morbidly obese NAFLD patients undergoing
laparoscopic sleeve gastrectomy surgery plus probiotic supplementation (Bio-25, Supherb, Israel) for
six months showed higher abundances of Actinobacteria and Collinsella in the experimental group
compared with the placebo. Although the alpha-diversity values never returned to the baseline levels
after the intervention, an incremental improvement was observed at Month 6 compared with Month 0,
and reductions were also observed at Month 12 vs. Month 6. However, the probiotic treatment did not
have any added benefits beyond the influence of the surgery itself with respect to hepatic improvement,
inflammatory or clinical outcomes [106]. Conversely, a prospective study that included 42 patients with
NAFLD observed that those subjects receiving prebiotics supplements and lifestyle modification (i.e.,
diet and exercise) showed significant improvement in parameters related to liver function compared
with those that only modified their lifestyle [102]. Similarly, prebiotic supplementation with inulin
following metronidazole therapy plus a very low calorie diet was shown to ameliorate decreased liver
function by reducing the levels of alanine aminotransferase in NAFLD subjects [107].
The potential benefits of probiotics administration have also been evaluated by Kobyliak et al.,
who reported that the co-administration of a probiotic with omega-3 in T2D patients with NAFLD
improved serum lipid levels and metabolic profiles and reduced liver fat levels and the chronic
systemic inflammatory state [108]. Along this line, the same group showed similar results after the
administration of a concentrated biomass of 14 probiotic bacterial genera (including Bifidobacterium,
Lactobacillus, Lactococcus, and Propionibacterium) [108]. However, in the abovementioned studies, details
regarding the changes in gut microbiota associated with the probiotics/prebiotics supplementation
were not described. In contrast, Ahn et al. [109] performed a study in which 68 NAFLD obese patients
were randomly divided into prebiotic (receiving a mixture of probiotics Lactobacillus acidophilus,
Lactobacillus rhamnosus, Lactobacillus paracasei, Pediococcus pentosaceus, Bifidobacterium lactis, and
Bifidobacterium breve) or placebo groups. In the probiotics group, but not in the control group, a
significant increase in all strains except Lactobacillus paracasei was observed as well as higher ratio
Bacteroidetes/Firmicutes. Those patients that presented fatty liver improvement also showed increased
abundances of Ruminococcaceae-2, Lachnospiraceae-2, Coprococcus, Lachnospiraceae-1, Ruminococcus, and
Dorea. Additionally, patients with successful weight loss presented increases in the abundances of
Ruminococcaceae-2, Ruminococcaceae-1, Clostridiales-2, Lachnospiraceae-2, and Coprococcus. All of these
changes were associated with fatty liver improvements.
The activation of inflammation due to both dysbiosis and alterations in intestinal permeability
via TLRs signaling in hepatocytes induces progression from simple steatosis to non-alcoholic
steato-hepatitis (NASH). This progression in dysbiotic NASH patients may be explained by the
cytotoxicity associated with the increase in primary fecal BA, the primary/secondary fecal BA ratio,
and plasma and hepatic BA concentrations [104]. Specifically, for NASH patients, therapies based
on prebiotic supplementation consisting of the ingestion of oligofructose for 24 weeks improved
liver histology independently of body weight. In addition, oligofructose increased the abundance
of Bifidobacterium, the incremental increase in which inversely associated with obesity and plasma
LPS [110]. Moreover, a 12-week treatment with a probiotic cocktail significantly altered the microbial
structure in the feces of the experimental group, increasing towards the normal range without
significantly altering the abundances of pathogenic enterobacteria and causing a significant decrease
in liver inflammation without other adverse events [111].
Similarly, Alisi et al. reported changes in gut microbiota of obese children associated with
the improvement of steatohepatitis and BMI after supplementation with VSL#3, a mixture of eight
probiotic strains (Streptococcus thermophilus, bifidobacteria (B. breve, B. infantis, and B. longum),
Lactobacillus acidophilus, L. plantarum, L. paracasei, and L. delbrueckii subsp. bulgaricus) for four
months [112]. In contrast, synbiotic supplementation only had positive effects on anthropometric
parameters associated with NASH (BMI, waist circumference, or uric acid levels) but not on gut
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permeability [113]. Most authors have concluded that modulation of gut microbiota brings added
benefits by itself or in combination with other interventions (i.e., diet, exercise, or bariatric surgery) to
NAFLD patients [106,108,114]. However, the heterogeneity of strategies (the use of pre- or probiotics,
the length of treatment, the grade of steatosis, the presence of inflammation, etc.) makes it mandatory
to understand and completely define what the precise changes causing the imbalance are and/or the
changes in gut microbiota that lead from hepatic health to fatty liver disease. Along this line, evidence
that the gut microbiota is altered in pediatric NAFLD and obese patients was investigated using
targeted metagenomics and metabolomics (Table 3). The authors concluded that the combination of a
low abundance of Oscillospira with high levels of 2-butanone may be a specific intestinal metagenomic
and metabolomic profile for liver steatosis in children. Moreover, pediatric NASH patients presented
high relative abundances of Lachnospiraceae, Ruminococcus, and Dorea. In addition, Blautia was extremely
high in NASH but not in NAFLD or obese children, while Oscillospira was significantly less abundant
in the NAFLD, NASH, and obese patients compared with controls, suggesting that changes in the gut
microbiota are associated with the severity of fatty liver disease [45]. In this regard, differences in the
microbiota of adult patients with biopsy-proven NAFLD, HCC, and fibrosis were also assessed. In this
study, the composition of gut bacteria was determined by sequencing of 16S rRNA gene, the results
of which showed decreased abundances of Bacteroidetes and Faecalibacterium prausnitzii in NAFLD
patients compared with the healthy controls.
Table 3. Microbiota changes associated with non-alcoholic fatty liver disease.
Reference Characteristics Intervention Time(weeks)
Methodological
Procedure Primary Results
Del Chierico et al.,
2017 [45]
61 children and
adolescents
(7–16 y/o). NAFLD
(n = 27), NASH
(n = 26), or obesity
(n = 58)
NA NA
Metagenomics and
metabolomics
analyses
Firmicutes, Bacteroidetes,
Proteobacteria, and
Actinobacteria were the
principal differences.
Kessouku et al.,
2017 [115]
201 adults.
NAFLD = 143
(77 mild fibrosis and
56 severe fibrosis)
NA NA
16S rRNA gene
sequencing and
blood endotoxin
activity assay
F. prausnitzii decreased in
NAFLD patients and
elevated blood-endotoxin in
NAFLD.
Lelouvier et al.
2016 [116]
44 adults (40–60 y/o)
BMI > 40. Fibrosis
71 blood and fecal
sample from Italy,
37 blood and 44 fecal
samples from Spain
NA NA
16S rRNA gene
quantitation by
qRT-PCR and 16S
metagenomic
sequencing
Changes in Sphingomonas
and Bosea correlated
significantly with fibrosis.
Ruminococcaceae,
Lachnospiraceae,
Coriobacteriaceae, and
Fusobacteriaceae are modified
in LF.
Anh et al., 2018
[109]
34 adults
Obesity plus NAFLD
Mixture of
lactobacilli and
bifidobacteria
12
qRT-PCR and 16S
rRNA gene
microbiome
sequencing
Fatty liver improvement
related to increases in
Ruminococcaceae-2,
Lachnospiraceae-2,
Coprococcus, Lachnospiraceae-1,
Ruminococcus, and Dorea.
Bomhof et al., 2018
[110]
Adults
NASH Oligofructose 24 Not indicated
Increase in Bifidobacterium.
Decreased Clostridium
clusters XI and I from
prebiotic supplementation in
patients with NASH.
Manzhalii et al.,
2017 [111]
38 adults
NASH
Probiotic cocktail:
lactobacilli,
bifidobacteria, and
S. thermophilus
12 Not indicated
Increased abundances of
bifidobacteria, Lactobacillus,
E. coli, and E. faecalis,
among others.
Abbreviations: BMI: body mass index; LF: liver fibrosis; NA: non-applicable; NAFLD: non-alcoholic fatty liver
disease; NASH: non-alcoholic steatohepatitis; RT-qPCR: quantitative polymerase chain reaction; rRNA: ribosomal
ribonucleic acid; y/o: years old.
Furthermore, endotoxin levels were observed to be higher in NAFLD patients with severe fibrosis
than in those with mild fibrosis, revealing that the mechanism of fibrotic progression via the endotoxin
in NAFLD may be strongly associated with gut permeability. The latest results suggest that the distinct
composition of the gut microbiota among NAFLD and HCC patients may offer a target for intervention
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or a marker for disease [115]. In addition, a recent study by Lelouvier et al. attempted to associate
microbiota dysbiosis from blood and feces with LF and BMI > 40 kg/m2 patients in two different
geographic populations. Only in one of the studied populations, specific bacterial taxonomic profiles
and their functions were associated with LF. This finding suggests that there is a potential interaction
between bacterial communities and an environmental factor specific to the geographical area in obese
patients [116].
In summary, available studies use a large variety of interventions (probiotic, prebiotics, symbiotic
supplementation, diet, or other approaches) and different patient baselines and treatment times (from
weeks to months), making it difficult to draw clear conclusions and highlighting the need for further
research in this field. From our point of view, the analysis of the gut microbiota under unhealthy
conditions remains to be defined, as well as how it is affected by diet, BMI, or age as well as others
factors, such as the grade of steatosis and geographical environment.
2.4. Insulin Resistance Syndrome
Insulin resistance syndrome (IRS) or metabolic syndrome is characterized by hyperinsulinemia
and an increased prevalence of obesity, hypertension, dyslipidemia, and T2D [117]. NAFLD is the
hepatic component of IRS [97].
IRS is currently a global burden, with 20–25% of the adult population worldwide suffering from
this disease [118]. In addition to genetic, lifestyle, and nutritional factors [119–121], alterations in gut
microbiota (dysbiosis) are also associated with IRS status [118,122–124]. The primary contributors to the
development of IRS are as follows: LPS from the gut microbiota, which can induce a chronic subclinical
inflammatory process through activation of TLR4; a reduction in circulating SCFA; alterations in the
secretion of glucagon-like peptide-1 (GLP-1) mediated by bile acids; and an increased circulation of
branched-chain amino acids (BCAA) [125].
The results of a metagenomic analysis performed with 58 IRS patients from Kazakhstan revealed
differences in gut microbiota composition of these patients compared with the healthy controls (e.g.,
significant reductions in the Firmicutes/Bacteroidetes ratio, bifidobacteria, and Subdoligranulum and
increased Prevotella). The results of this study disagree with previously published studies that were
primarily performed with European subjects in whom an increased Firmicutes/Bacteroidetes ratio
was observed, a discrepancy that is probably due to the dietary, lifestyle, and geographical features of
the Kazakh population [126].
With the purpose of reversing the different IRS-associated changes that occur in the gut microbiota
and reduce the impact of this disease, different approaches are being investigated to increase
the therapeutic strategies available to combat this syndrome (Table 4). Among these strategies
are dietary changes, nutritional supplementation, and the administration of prebiotics, probiotics,
FMT [81,127–133], and antibiotics [134]. Haro et al. evaluated the consumption of both a Mediterranean
and a low-fat diet in 138 IRS patients for two years. Firstly, they observed higher abundances of the
genera Bacteroides, Eubacterium, and Lactobacillus and reduced abundances of B. fragilis group members,
P. distasonis, B. thetaiotaomicron, F. prausnitzii, F. nucleatum, B. longum, B. adolescentis, the R. flavefaciens
subgroup, and E. rectale in IRS patients at time 0. After the intervention, only the Mediterranean diet
had induced significant changes (increased abundances of P. distasonis, B. thetaiotaomicron, F. prausnitzii,
B. adolescentis, and B. longum) in IRS patients, suggesting that, although IRS persisted after the
intervention, a Mediterranean diet may contribute to partially restoring the beneficial components of
the gut microbiota [135]. These authors also performed a similar study (an evaluation of the effect of
Mediterranean and low-fat diet for two years) in 33 obese patients with severe IRS versus 32 obese
patients that did not fulfill IRS criteria and 41 normal-weight subjects. In this study, they observed a
significant decrease in the Firmicutes/Bacteroidetes ratio after the consumption of the low-fat diet,
but only a decreasing trend for the Mediterranean diet. Additionally, the abundances of the genera
Bacteroides, Prevotella, and Faecalibacterium increased in IRS patients for both diets, Mediterranean and
low-fat, and reduced abundances of the genera Streptococcus and Clostridium were also observed in
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the low-fat diet group. In contrast, the group that received the Mediterranean diet did not exhibit
changes in the abundance of these genera but did exhibit increases in those of the genera Roseburia
and Ruminococcus and in the bacterial species P. distasonis and F. prausnitzii. Regarding the effect of
these diets on metabolic parameters, the triglyceride levels decreased in the IRS group and remained
unchanged in the other groups. These results suggest that the chronic intake of Mediterranean or
low-fat diets partially ameliorates the gut microbiome dysbiosis in severe IRS patients but that this
improvement depends on the degree of the metabolic dysfunction [136].
Table 4. Microbiota changes associated with insulin resistance syndrome.
Reference Characteristics Procedure Main Results
Kushugulova et al., 2018
[126] 58 IRS patients
16S rRNA gene
sequencing
IRS patient showed reduced
Firmicutes/Bacteroidetes ratio, Bifidobacteria and
Subdoligranulum and increased Prevotella.
Haro et al., 2017 [136]
33 adult obese patients
with severe IRS vs. 32 non
IRS obese patients and 41
normal-weight subjects
16S rRNA gene
sequencing
After administration of MD and LF diet for 2
years, MD decreased the F/B ratio, Bacteroidetes,
Bacteroides and Prevotella, and increased
Faecalibacterium in the IRS group.
Haro et al., 2016 138 IRS patients 16S rRNA genesequencing
At time 0, increased Bacteroides, Eubacterium. and
Lactobacillus genera and reduced the fragilis group,
P. distasonis, B. thetaiotaomicron, F. prausnitzii,
F. nucleatum, B. longum, B. adolescentis, the
R. flavefaciens subgroup, and E. rectale in IRS
patients at time 0. In a two-year intervention,
Mediterranean diet and low-fat high-carbohydrate
diet partly restored P. distasonis, F. prausnitzii,
B. thetaiotaomicron, B. adolescentis, and
B. longum levels.
Salonen et al., 2014 [137] 12 adult IRS patients
HITChip phyloge
Neticmicroarray and
q-PCR
Dietary intervention: 1 week M diet, 3 weeks RS
diet, 3 weeks NSP diet, and 3 weeks WL diet.
Multiple Ruminococcaceae phylotypes increased
with the RS diet, and Lachnospiraceae phylotypes
were primarily increased by the NSP diet.
Moreno-Indias et al.,
2015 [138] 10 adult IRS patients RT-PCR
Intake of wine and de-alcoholized red wine for
30 days/each increased bifidobacteria and
Lactobacillus and Faecalibacterium prausnitzii and
Roseburia and decreased Escherichia coli and
Enterobacter cloacae.
Ni Y el al., 2018 [139] 12 elderly IRS patients(60–90 y/o)
16S rRNA gene
sequencing
YDT supplementation for 4 days reduced
Bacteroidales Incertae Sedi, Enterobacteriaceae Incertae
Sedis and circulating lipoprotein(a) in correlation
with Acinetobacter species.
Roager et al., 2019 [140] 50 IRS patients 16S rRNA genesequencing
Administration of whole vs. refined grains for
8 weeks increased F. prausnitzii, P. copri, and
Clostridiales but decreased B. thetaiotaomicron.
Smits et al., 2018 [134] 10 adults IRS 16S rRNA genesequencing
Vegan FMT increased the levels of Lachnospiraceae,
especially B. formatexigens and M. hypermegale, as
well as L. bovis.
Velikonja et al., 2018
[141] 27 adults IRS patients
qRT-PCR, and 16S rRNA
gene sequencing
β-Glucans induced an increase in A. rectalis and
decreased the levels of Coriobacteriales and
Clostridiales associated with a reduction in total
plasma cholesterol.
Stadlbauer et al., 2015
[142] 13 adults IRS patients
16S rRNA gene
sequencing
Intake of LcS for 12 weeks increased Parabacteroides
but did not restore the gut microbiota composition,
gut barrier, or Bacteroidetes/Firmicutes ratio.
Vrieze et al., 2014 [143] 100 adults IRS patients
qRT-PCR and Human
Intestinal Tract Chip
microarray
Administration of 500 mg/day of vancomycin for
1 week reduced Gram-positive bacteria (especially
Firmicutes), secondary bile acids and peripheral
insulin sensitivity while increasing Gram-negative
bacteria (especially Proteobacteria) and reducing
peripheral insulin sensitivity.
Abbreviations: F/B: Firmicutes/Bacteroidetes ratio; FMT: fecal microbiota transplantation; IRS: insulin resistance
syndrome; LcS: Lactobacillus casei Shirota; M: standard diet at weight maintenance; MD: Mediterranean diet; NSP:
high in non-starch polysaccharides; qRT-PCR; quantitative polymerase chain reaction; rRNA: ribosomal ribonucleic
acid; RS: one high in type 3 resistant starch; V4: hypervariable 16S region; YDT: Yangyin Tiluo Decoction; y/o:
years old.
Salonen et al. reported on changes in the gut microbiota of 14 IRS patients fed four different diets
in a sequential fashion for 10 weeks as follows: (1) a standard diet for weight maintenance (M) for
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one week; (2) a diet with a high content of type 3 resistant starch (RS) for three weeks; (3) a diet with
a high content of non-starch polysaccharides (NSP) for three weeks; and, (4) a weight loss diet with
high protein and medium carbohydrate levels (WL) for another two weeks. The main results after
the different diet interventions were as follows: the RS diet increased Ruminococcus-related bacterial
phylotypes and the microbiota diversity, the NSP diet primarily led to increases in the abundance of
Lachnospiraceae, and the WL diet reduced the bifidobacteria. Notably, the dietary responsiveness of the
microbiota varied substantially among patients and was inversely associated with their diversity. This
result suggests that individuals can be stratified into responders and non-responders based on the
features of their intestinal microbiota. A positive correlation between fecal bifidobacteria and plasma
insulin was also detected in IRS patients [137].
Another strategy to modulate the gut microbiota composition through nutritional
supplementation in IRS was described in a study by Moreno-Indias et al. performed with 10 IRS
patients. The intake of two red wines of equal composition except for the ethanol content (regular
and ethanol-free red wines) for 30 days significantly increased the number of fecal bifidobacteria,
Lactobacillus and butyrate-producing bacteria (Faecalibacterium prausnitzii and Roseburia) at the expense
of less desirable groups of bacteria, such as LPS producers (Escherichia coli and Enterobacter cloacae).
These changes were attributed to the polyphenols present in both wines, and were associated with
a reduction in IRS risk markers, triglycerides, HDL-cholesterol, glucose, and glutamic pyruvic
transaminase [138]. A study by Ni et al. observed higher proportions of Lactobacillus and
Bifidobacterium and reduced abundances of Anaerostipes, Coprococcus, and Ruminococcus in 12 elderly
IRS patients compared with healthy individuals of the same age. A four-week treatment with Yangyin
Tiluo Decoction (a Chinese Herbal Formula) decreased the abundance of the order Bacteroidales.
Lipoprotein(a) levels were also reduced in plasma in correlation with the abundance of Acinetobacter
species [139].
Whole grain has been described to increase the abundances of Faecalibacterium prausnitzii,
Prevotella copri, and Clostridiales and decrease those of Bacteroides thetaiotaomicron compared with
a refined grain diet. Whole grain ingestion reduced body weight and systemic low-grade inflammation
but did not alter insulin sensitivity [140].
With respect to interventions with prebiotics and probiotics, the intake of barley β-glucans for
four weeks by 27 IRS patients induced an increase in the abundance of Agathobacter rectalis and
decreased that of Coriobacteriales and Clostridiales and was associated with a reduction in total plasma
cholesterol [141]. In a 12-week study, Stadlbauer et al. evaluated the effect of Lactobacillus casei Shirota
in 28 IRS patients (13 patients took β-glucans and 15 did not). Despite inducing an increase in the
abundances of Parabacteroides and Lactobacillus casei Shirota, the supplementation did not restore gut
microbiota composition, the gut barrier or the Bacteroidetes/Firmicutes ratio [142].
Smits et al. tested an FMT-based strategy in 20 patients with IRS [134], where patients received
feces from vegan donors and another 10 patients received their own feces. Feces from vegans
induced subtle changes, such as increased abundances of several microbial groups belonging to the
Lachnospiraceae family, including bacteria related to Bryantella formatexigens and Megamonas hypermegale
as well as L. bovis two weeks after transplantation. However, FMT did not induce any improvement
in parameters related to vascular inflammation. Furthermore, no changes occurred in the group of
patients that was subjected to autologous transplantation [134].
With regard to the use of antibiotics, the effect of oral vancomycin treatment (500 mg for seven
days) on the gut microbiota in 10 IRS patients was described by Vrieze et al. [143]. The primary
findings of this study were a reduction in fecal microbial diversity, a decrease in Gram-positive
bacteria (especially Firmicutes) with a concomitant increment in Gram-negative bacteria (especially
Proteobacteria). Vancomycin also decreased the levels of fecal secondary bile acids with a simultaneous
postprandial increase in primary circulating bile acids, which was associated with an altered abundance
of Firmicutes. With respect to metabolic effects, the administration of vancomycin reduced peripheral
insulin sensitivity [143].
Microorganisms 2019, 7, 68 14 of 27
Overall, findings supporting the beneficial effects of various interventions (diet, prebiotics,
probiotics, FMT, etc.) on gut microbiota as a strategy to treat IRS appear to be scarce and modest. In
addition, the persistence of these changes remains to be evaluated. In our view, both the number of
studies and enrolled patients are small, and the inter-individual variation between patients should
also be considered. Consequently, further research in this area of study is required to address the
aforementioned weaknesses.
2.5. Diabetes Mellitus Type II
Over 60 million people are diagnosed with T2D in Europe [144]. According to WHO, diabetes
will be the seventh leading cause of death in 2030 [145]. Factors such as a healthy diet, regular
physical activity, and body weight maintenance at normal levels prevent T2D development, delay its
progression, and help mitigate its pathological consequences. Prediabetes and high blood glucose
levels maintained over time without symptomatology are associated with overweight and obesity.
Because prediabetes leads to the development of diabetes in 70% of cases, a prevention strategy is
highly recommended in this state. T2D could be linked to the gut microbiota composition, and it
is directly responsible for the induction of a low-grade inflammatory state. The composition of the
gut microbiota also plays a significant role in the development of pre-diabetes conditions such as
resistance to insulin. The main alterations in gut microbiota associated with T2D have a significantly
lower prevalence of Firmicutes and enrichment of Bacteroidetes and Proteobacteria [140].
Growing evidence indicates that functional foods, such as prebiotics, probiotics, and postbiotics,
may be used in the prevention and treatment of diabetes [146–148]. Table 5 summarizes
microbiota-targeted interventions for T2D.
Totum63 is an association of plant principles for the treatment of T2D and prediabetes. In db/db
mice, a well-established obesity-induced animal model of TD2 in which mice carry a mutation in
the leptin receptor gene, Totum63 delayed the defect in insulin secretion, suggesting a protective
role on pancreatic beta-cells. Furthermore, in a phase I/II clinical trial Totum63 administration also
induced improvements in glucose levels and insulin response to a standardized breakfast in healthy
participants. Moreover, Totum63 treatment has been described to prevent the dysbiosis induced by a
high fat diet [149].
Metformin is the most frequent treatment used for T2D, and this drug has been reported to
significantly decrease the abundance of opportunistic bacteria [150] and significantly increase that of
beneficial bacteria, particularly Blautia spp. Moreover, a Chinese herbal formula has been reported
to increase Blautia and Faecalibacterium abundances in an open label study in T2D patients. Both
treatments were linked with diabetes improvements with respect to glucose levels, a homeostasis
model assessment of insulin resistance (HOMA-IR), and lipid homeostasis [151].
Canfora et al. studied the effects of GOS in 44 obese/overweight pediatric individuals [152].
The supplementation of diets with GOS increased the abundance of Bifidobacterium species in feces,
while the microbial richness and diversity in fecal samples was unaffected. No differences in fecal
or fasting plasma SCFA concentrations or in the systemic concentrations of gut-derived hormones,
incretins, LPS-binding protein, or other markers of inflammation were observed. In addition, no
significant alterations in peripheral and adipose tissue insulin sensitivity, body composition, or energy
and substrate metabolism were observed [152].
The microbiome may also be involved in determining how glycemic control impacts weight
change for different diets. The administration of SCFAs has been reported to result in a wide range
of health benefits, including improvements in blood lipid profiles, glucose homeostasis, and body
composition as well as in reduced body weight [148]. High butyrate levels were observed to be
associated with beneficial effects on insulin sensitivity and glucose levels [153,154]. A randomized,
double-blind study was carried out with 81 T2D patients divided into two three-month treatment
groups one group took a placebo, while the other group followed a reduced-energy diet comprising
high-fiber, polyphenol-rich, and vegetable-protein functional foods. Intervention with the last diet
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significantly modified fecal microbiota compared with the placebo, increasing the abundances of
F. prausnitzii and A. muciniphila and decreasing that of P. copri.
SCFAs are produced by various human gut microbes. SCFAs act as an energy source to the
colonic epithelium and are also sensed by host signaling pathways that modulate appetite and
inflammation. A deficiency in gut SCFAs is associated with type 2 diabetes. Zhao et al. observed that
a high-fiber diet promoted the growth of SCFA-producing organisms in diabetic humans [147,155].
Furthermore, the high-fiber diet induced changes in the entire gut microbe community and correlated
with elevated levels of glucagon-like peptide-1, a decrease in acetylated hemoglobin levels, and
improved blood–glucose regulation [147,155].
In a clinical trial with T2D patients, the relative abundance of A. muciniphila, a mucin-associated
bacterium with anti-inflammatory properties, increased after inulin and sodium butyrate prebiotic
supplementation [156–158].
A type of black tea from China contains some polysaccharides and polyphenols that improve
glucose and lipid metabolism in prediabetic subjects by modifying the gut microbiota (decreasing
Faecalibacterium and Oscillospira). In particular, GLP-1 and GLP-2 serum levels increased after 12 weeks
in the group of patients that drank the tea compared with those who received a placebo [159].
Another dietary resistant starch-based prebiotic has been shown to positively affect metabolic
health markers. In humans, resistant starch fermentation may enhance the abundances of specific gut
microbiota taxa, such as Bifidobacterium, Ruminococcus bromii, and Eubacterium rectale, with associated
improvements in insulin response, body fat reserve, and cholesterol levels [160]. Transglucosidase
(TGD) produces oligosaccharides from starch in the human intestinal tract. Shimozato et al. observed
that TGD administration to patients with T2D for 12 weeks significantly affected the fecal microbiota
content, increasing Clostridium cluster IV, Clostridium subcluster XIVa, Clostridium cluster XVIII, and
fecal pH and decreasing the order Lactobacillales in patients with bowel movement disorder compared
with the controls. The TGD treatment significantly improved bowel movements compared with the
placebo treatment, and this effect was not observed in patients without bowel movement disorder [161].
Table 5. Microbiota changes associated with diabetes mellitus type II.
Reference Characteristics Procedure Primary Results
Stefanaki et al., 2018
[163]
RCT with 50 adolescents. Probiotics
and healthier lifestyle interventions
Body composition, glycemic
and gut microbiota
measurements
Probiotic administration was safe and
useful for preventing the onset of
pre-diabetes.
Tong et al., 2018
[151]
RCT in T2D and hyperlipidemia
patients for 12 weeks with
metformin and Chinese medicine
treatment in 450 patients
16S rRNA gene (V3 and V4
regions) sequencing
Significantly decreased hyperglycemia
and hyperlipidemia, enrichment in
Blautia and Faecalibacterium spp.
Zhao et al., 2018
[155]
43 Chinese patients administered a
high-fiber diet/prebiotics and a
control. Both groups were treated
with acarbose
Identification of
SCFA-producing bacterial
strains by metagenomic
sequencing
Increased SCFA levels in the human
bowel of the dietary fibers/prebiotics
group. Improvement in hemoglobin
A1c levels by elevating glucagon-like
petide-1 production.
Roshanravan et al.,
2018 [164]
59 overweight and obese patients
with T2D received sodium butyrate,
inulin powder or both or a placebo
16S rRNA gene analysis of
A. muciniphila by quantitative
real-time PCR
Increased A. muciniphila and decreased
TNF-αmRNA expression.
Medina-Vera et al.,
2018 [147]
81 patients with T2D divided into
placebo and functional food-based
diet (high fiber, polyphenol rich and
vegetable protein) groups
Determination of fecal
microbiota
Increased F. prausnitzii and
A. muciniphila and decreased P. copri.
Improvement in glucose, insulin,
HOMA-IR, and LPS levels.
Elbere et al., 2018
[150]
18 healthy subjects were treated
with metformin for 7 days 16S rRNA gene (V3 region)
Diversity of gut microbiota decreased
(reduction of Peptostreptococcaceae and
Clostridiacea_1) after metformin
treatment.
Shimozato et al.,
2017 [161]
66 T2D patients with and without
chronic bowel movement disorder
treated with placebo or
transglucosidase
Analysis of fecal microbiota
(amplification of 16S rRNA
gene with T-RFLP)
Transglucosidase treatment modified
the fecal microbiota (Prevotella,
Bacteroides, Bifidobacterium, and the
Clostridium sub-cluster XIVa) and the
fecal SCFA and significantly improved
bowel movements.
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Table 5. Cont.
Reference Characteristics Procedure Primary Results
Canfora et al., 2017
[152]
Supplementation with
galacto-oligosaccharides in 44
prediabetic patients
Fecal microbiota composition
Galacto-oligosaccharide
supplementation
increased Bifidobacterium.
Sato et al., 2017
[146]
Supplementation with L. casei in 68
T2D patients Analysis of fecal microbiota
Probiotic administration increased
C. coccoides, C. leptum, and Lactobacillus.
Mobini et al., 2016
[162]
46 patients with T2D on insulin
therapy and L. reuteri DSM 17938
supplementation
Fecal microbiota composition No changes in microbiotawere observed.
Abbreviations: PCR: polymerase chain reaction; RCT: randomized clinical trial; mRNA: messenger RNA; rRNA:
ribosomal ribonucleic acid; SCFA: short chain fatty acid; T2D: type 2 diabetes; TMAO: trimethylamine N-oxide;
TNF-α: tumor necrosis factor alpha; TRFLP: terminal restriction fragment length polymorphism; V3 or V4:
hypervariable 16S region.
Several lines of clinical evidence suggest that the use of probiotics as alternative therapeutics
against T2D increases the quality of life [146,162–164]. Some clinical trials were reviewed to confirm
the beneficial effects and deepen understanding of the underlying mechanisms [165], resulting in a
combination of life-style intervention and probiotic supplementation in prediabetic adolescents being
proposed [163]. The efficacy of probiotics appears to depend on the bacterial strain and the study
outcome. Lactobacillus casei strain Shirota-fermented milk was investigated in T2D pathologies, the
results of which confirmed that this probiotic reduced bacterial translocation in Japanese individuals
with T2D [146]. Furthermore, the administration of Lactobacillus reuteri to T2D patients has been
shown to improve insulin sensitivity [162] (Table 5). As for postbiotics, defined as secreted factors,
cellular components and metabolites of bacteria that, upon delivery to a host, may exert biological
effects on it. Microbial components from live or dead bacteria can also be considered a source of
postbiotics. Examples of postbiotics such as microbial-derived short-chain fatty acids or flavonoids may
directly influence host feeding behavior, energy metabolism, insulin secretion, and insulin sensitivity.
These postbiotic properties should be considered in obesity-related metabolic disease and represent a
promising alternative to current treatments [166].
Figure 1 summarizes the microbiota alterations in particular pathologies as well as
current therapies.
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Figure 1. Schematic representation of the microbiota alterations in various disorders and the current therapies to counteract their effects. Abbreviations. DC: dendritic
cells; NAFLD: non-alcoholic fatty liver disease; SCFA: short-chain fatty acids.
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3. Future Directions
Maintaining a healthy gut ecosystem is essential, and alterations in the diversity, quantity, and
stability of a healthy microbiota has been associated with obesity, IBD, and IRS as well as other
metabolic disorders such as NAFLD and T2D. Since the prevalence of these diseases continues to
rise worldwide, the modulation of the gut microbiota through various interventions (e.g., prebiotics,
probiotics, and FMT) is a research area of increasing interest given their potential as tools to prevent
or treat these diseases. However, conflicting results and limited efficacy have been reported to date.
The different durations and doses of the interventions, as well as the technology used for sequencing
the microbiome makes comparisons among studies difficult. 16S approaches for microbiome analyses
are well suited for analysis of a large number of samples, i.e., multiple patients, longitudinal studies,
and so on. However, this approach offers limited taxonomical and functional resolution. Moreover,
it should be pointed out that using primers for different regions of the 16S rRNA gene may lead
to discordant results due not only to the distinct binding affinities for the corresponding flanking
conserved regions, but also due to the resolution of each variable region across taxa [167]. In contrast,
shotgun metagenomics is usually more expensive but offers increased resolution, enabling a more
specific taxonomic and functional classification of sequences, as well as the discovery of new bacterial
genes and genomes [168].
FMT, which has yielded promising results for treating certain disorders, such as Clostridium difficile
infections, is a clear example of this issue and should be addressed in future studies. Stool donor
preparation and the transplantation method (endoscopy, nasointestinal tubes, or capsules) must be
standardized, and the long-term potential adverse effects should be studied in greater detail.
Among the next-generation beneficial microbes that have been identified, Akkermansia muciniphila
and Faecalibacterium prausnitzii are promising candidates. A. muciniphila has been reported to be
inversely associated with obesity, diabetes, cardiometabolic diseases, and low-grade inflammation.
Besides the numerous correlations observed, a large body of evidence has demonstrated the causal
beneficial impact of this bacterium in a variety of preclinical models [169]. Many studies have shown
that F. prausnitzii abundance is reduced in different intestinal disorders. It has been proposed that F.
prausnitzii monitoring may therefore serve as a biomarker to assist in gut diseases diagnostics [170].
Testing these strategies in many more clinical trials and with great numbers of human subjects is
clearly needed.
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